Phase 2 Trial Completes Enrollment for Novel Obesity Drug LY3305677 (Mazdutide)
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
Abstract
A Phase 2, Parallel-Group, Double-Blind, 4-Arm Study to Investigate Weight Management With LY3305677 Compared With Placebo and in Adult Participants With Obesity or Overweight
NCT ID: NCT06124807
Status: COMPLETED
Sponsor: Eli Lilly and Co…